1. New Light Path TM Services

2. slide 2 Light Path TM : streamlined custom material supply for discovery to early development n Leverage Lonza’s proven technology platforms & expertise to meet your exact early development needs in a lean, cost effective and speedy manner n Complete gene to GMP production service offerings for both microbial & mammalian technology n Partner with Lonza early and be on the road to a marketable product preclinical development phase I drug discovery mg kg non-GMP GMP

3. slide 3 Meet all your discovery, pre-clinical & phase 1 material needs with Light Path TM Preclinical Development Phase I Drug Discovery 1g – 1000 g, non GMP in 6 to 10 weeks 1mg – 500mg, non GMP in 6 to 10 weeks Light Path™ Discovery 1 - 100 grams, non-GMP in 4 to 8 months 1g - 1000 grams, GMP in 3 to 6 additional months Light Path™ Development * starting from gene sequence, timeline guidance includes gene synthesis.

4. Mammalian Light Path TM Services

5. slide 5 Mammalian Light Path TM Discovery for custom milligram material supply (non-GMP) n Product expression using Lonza’s proprietary GS Gene Expression System™ n Option to perform vector construction suitable for future stable cell line development n Option to apply your specific affinity chromatography step n Option to monitor endotoxin levels and include additional purification steps n Material supply for multiple product candidates Protein A or similar affinity step Delivery of up to 500mg of product Gene synthesis Product Expression Affinity Chromatography Vector Construction Vector construction DNA amplification Transient expression or Transfectant pool Culture Preparation Material Supply clarified supernatant up to 10L

6. slide 6 Mammalian Light Path TM Development for pre-clinical through to your IND Starting from a gene sequence: Streamlined PD non-GMP Pilot Supply Option (1-100g) Cell Line Construction GMP Production (10g – 1000g ) Pre-production Activities option for mg supply via Light Path™ Discovery

7. slide 7 Compare Mammalian Light Path TM Development to Lonza’s standard GMP programs ServiceStandardLight Path Cell line Construction n Options for development of unclonal or clonal cell lines n Vector construction, transfection and multiple rounds of cell line screening where applicable n Cell line stability study on three candidate cell lines n Supply of up to 5 mg of Protein A purified product from top 9 selected cell lines n Options for development of transfectant pool, unclonal or clonal cell line n Vector construction, transfection and limited rounds of cell line screening where applicable n No cell line stability study unless requested n Supply of up to 5mg of Protein A purified product from top 9 selected cell lines Upstream Development n Application and evaluation of Lonza’s platform upstream process n Performance of 2x10L scale and material supply for purification process development n Material supply of up to 5mg Protein A purified product for animal efficacy studies n Application of Lonza’s platform upstream process only n Performance of 2x10L lab scale for purpose of material supply for purification evaluation only

8. slide 8 ServiceStandardLight Path Downstream Development n Application and evaluation of all steps of Lonza’s platform downstream process n Intermediate product stability study n Assumes product is a monoclonal antibody of subclass IgG1, 2 or 4 with pI>8 and aggregate levels of <10 n Evaluation of limited steps of Lonza’s platform downstream process to a “good enough” level n No intermediate product stability study Analytical Development n Evaluation of Lonza’s Protein A HPLC and all batch release platform assays n Evaluation of limited subset of platform assays Pilot Production n Non-GMP runs at 130L, 250L or 400L scale (tox material supply) n No non-GMP pilot run unless requested GMP Production n Any scale n 200L, 500L, 800L, 1000L *only size available for transfectant pool option Compare Mammalian Light Path TM Development to Lonza’s standard GMP programs - continued

9. slide 9 Decide if Mammalian Light Path TM Development is right for you n Take the Light Path™ when your focus is strictly on filing an IND n If certain budgetary restrictions would require scope limitations, then Lonza will focus on only necessary activities n Light Path™ requires an in-depth discussion with Lonza to agree in partnership on how to best design you program. Lonza will highlight areas where potential challenges may arise that could require scope change. n Leverage of Lonza’s proven GS expression system™ and processes development platforms to generate an IND enabling

10. Microbial Light Path TM Services

11. slide 1125-Jun-16 Microbial Light Path TM Discovery for custom milligram material supply (non-GMP) 4x500mL Fermentation Empty Vector Strain 1 Strain 3Strain 2 IMA C Tag removal & DS Dev Purification Delivery option 3 Fermentation XS Strain Development Client Strains Tag removal Expression of tagged proteins Affinity Chrom. Tag removal or downstream “scouting” w/ parallel expression of untagged protein Final purification run Strain Acquisition or Delivery option 2 Delivery option 1 n Option to start with a minimal XS E. coli strain development to explore expression feasibility n Default service assumes His-tagged protein, option to have His-clipped version n Option to have a minimal DSP development performed to purify untagged native product n Deliverable is 1-500 mg target protein at >70% purity. n Actual quantities delivered depend on expression levels and DSP yields achieved n Light path™ Discovery XS strain can be used as the starting point for Light Path™ development service

12. slide 12 Microbial Light Path TM Development for pre-clinical through to your IND Starting from a gene sequence: Streamlined PD non-GMP Pilot Supply Option (1-100g) XS Strain Development GMP Production (10g – 1000g ) Pre-production Activities Drop-in an existing process: option for mg supply via Light Path™ Discovery non-GMP Pilot Supply Option (1-100g) Transfer / Adapt / Minimal Development GMP Production (10g – 1000g ) Pre-production Activities option for mg supply via Light Path™ Discovery Customer Strain & Process

13. slide 13 Compare Microbial Light Path TM Development to Lonza’s standard GMP programs ServiceStandardLight Path Strain Development n Evaluate a variety of expression systems and hosts (E. coli, pichia, bacillus) n Full fermentation screening via 4 x 4 1L DASGIP runs n Explore most attractive options only n Reduced scope of fermentation screening (only 2 x 4 1L DASGIP runs) Fermentation Development n Perform 18 x 10L fermentations n Screen up to 8 parameters to establish a robust process n Perform only 3 x 4 1L DASGIP runs PLUS 4 x 10L fermentations n Screen only 3 parameters to establish a “good enough” process Downstream Development n Develop 3-4 chromatography steps n Screen 6 resins per chromotography step n Develop 2 TFF steps n Assumes 2 or 3 chromatography steps are sufficient n Screen 3 resins per chromotography step n Assumes 1 TFF step is sufficient Lab Consistency & Pilot Runs n Perform up to 4 consistency runs (10L) n Multiple pilot runs at 20L, 40L or 200L scale (can supply tox needs) n Perform only 2 consistency runs (10L) n Encourage at least one pilot run, but not always necessary GMP Production n Lay down Master & Working Cell Banks n 1 to 2 engineering runs before initial GMP batch n Any GMP scale n Lay down only Master Cell Bank n First and only engineering run can be released as GMP if successful n GMP scales limited to 20L, 150L & 800L (total volumes) * * Lonza will not transfer into GMP with significant risk of failure. Additional scope change may be needed to establish an adequate process.

14. slide 14 Decide if Microbial Light Path TM Development is right for you n Take the Light Path™ when your focus is strictly on filing an IND n If certain budgetary restrictions would require scope limitations, then Lonza will focus on only necessary activities n Light Path™ requires an in-depth discussion with Lonza to agree in partnership on how to best design you program. Lonza will highlight areas where potential challenges may arise that could require scope change. n In lieu of costly non-GMP engineering runs at scale, Lonza will establish your IND-enabling GMP process in a cost-efficient pilot laboratory environment n Lonza will not proceed into GMP without sufficient data to indicate that the process has a high likely hood to initially succeed at scale on the first run